baber/WOPTO huggingface dataset:
Patent NZ-569943-A (NZ)
Title: Return spring assembly for a door which alternately compresses a spring depending on rotation direction
Inventor: ZIMMER TODD C
IPC: E05C19/00
Filed: 2006-11-02
Abstract: Disclosed is a return spring assembly (10) for a lock mechanism adapted for installation in a bored opening in a door. The assembly includes a spring housing (12), a compression spring (30), and first (32) and second (34) spring drivers. The housing has an outer flange (14) that makes supporting contact a face of a door, the outer flange having a greater diameter than the bored opening, and an inner portion (16) extending into the bored opening with a curved section (20) and an annular spring channel (28). The curved section extends more deeply into the bored opening. The first spring driver has an arm (36) engaging a first end of the spring and the second spring driver has an arm (42) engaging a second end of the spring. Each spring driver includes a center (52, 54) to engage a spindle driven by a handle. The spring drivers alternately compress the spring from opposite directions as the handle is rotated in opposite directions.
Patent NZ-576406-A (NZ)
Title: Combined air pulsator and movable pedestal
Inventor: HELGESON LONNIE J
IPC: A62B7/00
Filed: 2007-11-07
Abstract: A portable human body pulsating apparatus (10) which has an air pulse generator (11) having a housing (12) mounted to a frame (41) that is on a pedestal (29) having wheels (38) to facilitate the movement of the apparatus. The pedestal has an upright piston and cylinder assembly (31) operable to adjust the elevation of the air pulse generator.
Patent NZ-581820-A (NZ)
Title: MYB from clover or medic
Inventor: SPANGENBERG GERMAN
IPC: A01H1/00
Filed: 2008-06-25
Abstract: Disclosed is a substantially purified or isolated nucleic acid or nucleic acid fragment encoding a MYB protein, or complementary or antisense to a sequence encoding a MYB protein, said nucleic acid or nucleic acid fragment including a nucleotide sequence as defined in the complete specification. Also disclosed is a method of modifying: flavonoid biosynthesis in a plant; protein binding, metal chelation, anti-oxidation, and/or UV-light absorption in a plant; pigment production in a plant; plant defence to a biotic stress; and forage quality of a plant by disrupting protein foam and/or conferring protection from rumen pasture bloat. The method includes introducing said nucleic acid into a plant.
Patent NZ-586439-A (NZ)
Title: Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt
Inventor: SIZER PHILIP J
IPC: G01N33/543
Filed: 2008-12-24
Abstract: Discloses a method for performing an immunodiffusion assay, comprising: (a) obtaining a starting composition comprising an influenza virus hemagglutinin (HA) antigen, wherein the HA antigen is adsorbed to an adjuvant that comprises an aluminium salt; (b) treating the starting composition with a mixture comprising a salt at a concentration range from 10mM to 1000mM and a surfactant at a concentration range from 0.1% to 15% (w/v) to desorb the HA antigen from the adjuvant; and (c) allowing the desorbed composition, comprising the desorbed HA antigen, to diffuse into a gel comprising an antibody specific to the antigen. The method finds application in determining an accurate level of influenza virus HA antigens in compositions containing aluminium salts, which had previously caused immunodiffusion assays to give inaccurate results.
Patent NZ-587774-A (NZ)
Title: Enteric solid oral dosage form of bisphosphonate containing a chelating agent
Inventor: DANSEREAU RICHARD JOHN
IPC: A61K9/00
Filed: 2005-04-14
Abstract: A kit comprising: (a) one or more oral dosage forms; and (b) means for facilitating compliance using a safe and effective amount of a pharmaceutical composition, wherein the one or more oral dosage forms comprises the safe and effective amount of a pharmaceutical composition comprising: (a) from about 1 mg to about 500 mg of a bisphosphonate which is selected from the group consisting of risedronate and acids, salts, and esters thereof; (b) from about 10 mg to about 1000 mg of a chelating agent; and (c) a delayed release mechanism to deliver the bisphosphonate and the chelating agent in the lower gastrointestinal tract.
Patent NZ-590725-A (NZ)
Title: A sulfated polysaccharide compound and the preparation and use thereof
Inventor: STAJIC VLADIMIR
IPC: A61K31/737
Filed: 2008-10-08
Abstract: 590725 Disclosed is a method of preparing sulphated glycan molecules involving at least two sulfation steps. For example sulphating xylan to xylan sulphate then hydrolysising to hydrolysed xylan sulfates and further performing a sulfation of the hydrolysed sulfate. Preferably the molecules comprise (a) one or more linear 1-4 conjugated beta-D-xylose units; and (b) at least one 4-O-methyl-[beta]-D-glucuronic acid unit attached to carbon-2 of every about eight to ten (on average) said xylose units.
Patent NZ-596219-A (NZ)
Title: Adhesive for textile reinforcing inserts and use thereof
Inventor: KAPLAN ANDREAS
IPC: C09J175/04
Filed: 2011-11-04
Abstract: 596219 Disclosed is a pulverulent adhesive for textile reinforcing inserts, which is dispersible in water, consisting of (A) 35   95 percent by weight of at least one at least partially capped, low-molecular isocyanate, (B) 0.1   10 percent by weight of at least one wetting agent, (C) 5   40 percent by weight of at least one binder, (D) 0   5 percent by weight of at least one catalyst, and (E) 0   10 percent by weight of at least one additive, the proportions of the components (A) to (E) adding up to 100 percent by weight, and wherein the at least one low-molecular isocyanate to be capped has a molar mass of less than or equal to 500 g/mol.
Patent NZ-600772-A (NZ)
Title: Pyridyl derivatives as CFTR modulators
Inventor: HADIDA-RUAH SARA
IPC: A61K31/44
Filed: 2009-03-25
Abstract: ABSTRACT - 600772 The disclosure relates to a pyridine-clopropane-carboxamide derivative of formula (I), and a pharmaceutically acceptable salt thereof, processes for its preparation, compositions comprising said compounds and uses thereof, wherein the variables are as defined in the specification. Said compound is useful as modulators of ATP-Binding Cassette (ABE) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"), as such are useful in the treatment of condition, disease, or disorder selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, diabetes mellitus, laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, hereditary emphysema, congenital hyperthyroidism, osteogenesis imperfecta, hereditary ypofibrinogenemia, ACT deficiency, diabetes insipidus (di), neurophyseal di, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus- Merzbacher disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, Huntington, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, myotonic dystrophy, as well as spongiform encephalopathies, hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, and Sjögren's disease.
Patent NZ-603944-A (NZ)
Title: Reinforced cross-laminated bulk container
Inventor: RONALD D TIMBROOK
IPC: B65D5/06
Filed: 2012-11-30
Abstract: 603944 A reinforced, cross laminated, corrugated paperboard bulk container (10’) is disclosed. The container has an outer component and an inner liner laminated to the outer component. Each of the outer component and the liner have corrugations and a reinforcing strand extending perpendicular to the corrugations. The liner corrugations extend perpendicular to the corrugations in the outer component. The bottom edges (31) of the sidewalls include a first pair of flaps (30A, 30B) and a second pair of flaps foldably extending from the bottom edge (31). The second pair of flaps have a pair of spaced apart triangularly shaped slots (44) which receive tabs (37a-d) of the first pair of flaps (30A, 30B). The container (10’) is especially adapted for containing fluid products.
Patent NZ-613331-A (NZ)
Title: Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
Inventor: BELAUBRE FRANÇOISE
IPC: A61K36/28
Filed: 2012-01-18
Abstract: Disclosed are monoterpene derivatives of chalcone or dihydrochalcone corresponding to formula I wherein R1 is H or CH3 and R2 is H or OH, and the use thereof as a depigmenting agent. Also disclosed are cosmetic or dermatological compositions comprising the compounds. The compounds are obtained as an extract of Helichrysum gymnocephalum.
Patent NZ-624361-A (NZ)
Title: Load retention webbing
Inventor: GEORGE SEMERTZIDIS
IPC: D03D15/12
Filed: 2014-04-30
Abstract: A webbing comprising an aramid warp and weft, and a polyester filling. The polyester filling is oriented in the warp direction.
Patent NZ-625386-A (NZ)
Title: Thrombin-binding antibody molecules and uses thereof
Inventor: HUNTINGTON JAMES ANDREW
IPC: C07K16/36
Filed: 2012-12-14
Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
Patent NZ-626680-A (NZ)
Title: Uses of immunoconjugates targeting cd138
Inventor: SCHULZ GREGOR
IPC: A61P35/00
Filed: 2012-12-07
Abstract: Disclosed is the use of an immunoconjugate in the manufacture of a medicament for treating a disease associated with target cells expressing CD138 in a human subject, the immunoconjugate comprising at least one engineered targeting antibody targeting CD138 expressing cells, and at least one effector molecule, wherein said engineered targeting antibody is functionally attached to said effector molecule to form said immunoconjugate, wherein at least a part of the engineered targeting antibody confers IgG4 isotype properties, wherein the disease associated with target cells expressing CD138 is a plasmaproliferative disorder or a solid tumour, wherein said treating comprises administering the immunoconjugate in a multiple dose regimen comprising at least two doses, wherein the aggregate dose to be administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD and wherein said AMTD or said fraction exceeds the dose resulting in dose limiting toxicity (DL T) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.
Patent NZ-713391-A (NZ)
Title: Tricyclic triazolic compounds as sigma receptors ligans
Inventor: DIAZ-FERNÁNDEZ JOSÉ-LUIS
IPC: C07D498/14
Filed: 2014-04-21
Abstract: The present invention relates to new tricyclic triazolic compounds of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for treating e.g. pain related diseases
Patent NZ-720910-A (NZ)
Title: A transformer and method of manufacture
Inventor: SEBASTIAMPILLAI RAYMOND
IPC: H01F27/40
Filed: 2016-06-08
Abstract: A transformer including a tube within the transformer windings that is wound with the windings to form a coil around the core. The tube is dimensioned to receive an optical fibre for measuring temperature and optionally other parameters. The temperature sensor may be one or more Bragg grating provided at intervals along the optical fibre. The optical fibre may pass through oil surrounding the transformer to allow measurement of parameters relating to the oil. The arrangement allows optical fibres to be installed or replaced after transformer manufacture.
Patent NZ-727432-A (NZ)
Title: Tungsten carbide-cubic boron nitride composite material and preparation method thereof
Inventor: ZHANG JIANFENG
IPC: C04B35/64
Filed: 2015-06-30
Abstract: A method of preparing tungsten carbide-cubic boron nitride composite material, employing chemical vapor deposition and high temperature sintering: first, respectively coating WC and cBN surfaces with nanoparticle layers, and then sintering at a high temperature to obtain bulk material. The produced tungsten carbide-cubic boron nitride composite material has characteristics of high structural thermostability, high hardness and the like, and can serve as the material for high-speed cutting blades.
Patent NZ-727953-A (NZ)
Title: Sheet Material Delivery System
Inventor: RICHARD JOHN HALBERT
IPC: E04F21/00
Filed: 2016-12-23
Abstract: A system for supporting one or more sheets of construction material, the system comprising: a support apparatus for supporting the one or more sheets of construction material in a generally upright configuration, the support apparatus comprising: a base upon which the support apparatus can stand and upon which an in-use lower edge of the one or more sheets can be supported when in the generally upright configuration; an upright extending up from the base in use; a surface arranged with respect to the upright, the surface oriented to support an inwardly facing surface of an innermost sheet when supported at the base, such that the innermost sheet leans towards the upright; and a lifting apparatus for lifting the support apparatus to a generally upright configuration, the lifting apparatus comprising: a support surface that is deployable between load and unload orientations, with the upright of the support apparatus able to lie on the support surface when in the load orientation; and a mechanism for causing the support surface to move between the load and unload orientations such that the support apparatus can be lifted to cause the upright to extend generally up, whereby the support apparatus is then able to stand on its base.
Patent NZ-730131-A (NZ)
Title: Biosensors for monitoring biomolecule localization and trafficking in cells
Inventor: BOUVIER MICHEL
IPC: C12Q1/66
Filed: 2015-09-21
Abstract: Bioluminescence resonance energy transfer (BRET) biosensors for assessing the intracellular localization, internalization and trafficking into cellular compartments of proteins such as receptors, and other biomolecules such as second messengers, are disclosed. These biosensors, which are dependent on the concentration/density of the BRET donor and acceptor in cellular compartments rather that specific protein-protein interactions, use a Renilla GFP/Luc BRET pair, which allows the robust and reproducible monitoring of protein trafficking/localization, with a sensitivity compatible with high-throughput screening (HTS). The use of these biosensors for various applications, including assessing/monitoring protein endocytosis, recycling and intracellular trafficking, receptor maturation/rescue by pharmacological chaperones, various endocytosis/exocytosis processes, activation/inhibition, as well as biomolecule concentration/density in different cellular compartments, is also disclosed.
Patent NZ-734176-A (NZ)
Title: Novel antitumoral use of cabazitaxel
Inventor: GUPTA SUNIL
IPC: A61P35/00
Filed: 2010-10-27
Abstract: Disclosed is the use of cabazitaxel which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, in the manufacture of a medicament for its use in treating prostate cancer in a patient, wherein the prostate cancer is an advanced metastatic disease, castration resistant prostate cancer or hormone-refractory prostate cancer, and wherein the patients treated have been previously treated with a docetaxel-based regimen.
Patent NZ-736029-A (NZ)
Title: Device and method for manufacturing welded shaped steel
Inventor: ASADA HIROSHI
IPC: B23K26/21
Filed: 2016-03-28
Abstract: The present invention makes it possible, even for welded section steel of asymmetrical shape in which sections of flange members have different degrees of thermal deformation after welding, to allow for corrections to the original cross-sectional configuration to be easily made. The present invention is provided with a correction apparatus (100) in which the ends of a web member (3) are caused to abut at right angles against flange members (1, 2) and the abutting sections are welded together, whereupon the shapes of the flange members having been thermally deformed by input heat during welding are then corrected. This correction apparatus has: flange member correction rollers (24) that are installed at the ends of the flange members and correct thermal deformation from the flange member ends to the sections abutting the web member by pushing the web member side of the ends of the flange members; and web member support rollers (44, 45) for supporting the web surfaces of the web member. The flange member correction rollers installed at the ends of the flange members correct the thermal deformation using pushing force independently at each end of the flange members.
Patent NZ-741124-A (NZ)
Title: Engineering t-cell receptors
Inventor: SMITH SHEENA N
IPC: C12N15/12
Filed: 2013-07-26
Abstract: Disclosed are modified T cell reeceptors binding a SURV:HLA-A2 survivin antigen MHC complex. The disclosed receptors are derived from the Tax specific A6 TCR and comprise amino acid substitutions at positions 31, 32, 97, 98 and 99 on the alpha chain and positions 30 99, 100 and 102 on the beta chain. The use of model T cell receptors (TCRs) as scaffolds for in vitro engineering of novel specificities is provided. TCRs with de novo binding to a specific peptide-major histocompatibility complex (MHC) product can be isolated by: 1) mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of TCR mutants with the specific peptide-MHC, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-MHC ligand. The process can be repeated to identify TCR variants with improved affinity for the selecting peptide-MHC ligand.
Patent NZ-750118-A (NZ)
Title: A fastening device for compacted plastic bottles intended for recycling
Inventor: AMSELLEM MAURICE MOSHE
IPC: B65D23/00
Filed: 2017-04-27
Abstract: A fastening belt for a recyclable, plastic, beverage bottle including: a length of flexible material affixed around a circumference of the bottle and positioned on a lower part of a body of the bottle; in a first partially compacted the material is disposed in a crease of a fold between the first and the second segments of the bottle; and in a second, compacted state, the material is configured to be passed over the neck of the bottle, thereby securing the first and second segments of the bottle in the compacted state folded over the third segment.The purpose of the environmentally friendly invention is to allow consumers to reduce the volume of plastic bottle waste ready for recycling with the simple and easy to use accessory which holds a compacted bottle in the compacted state so that the bottle taken up less space.
Patent NZ-755091-A (NZ)
Title: Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
Inventor: SMITH ERNEST S
IPC: A61K31/664
Filed: 2014-06-20
Abstract: Provided is a method of selecting subjects with cancer for treatment with an isolated antibody or antigen-binding fragment thereof which specifically binds to semaphorin-4D (SEMA4D) in combination with at least one other immune modulating therapy, the method comprising: (a) determining the number of B cells and/or T cells in a sample previously obtained from a subject with cancer; and (b) selecting said subject for treatment if the number of B cells and/or T cells per microlitre of blood in the sample is at least 1.5 times the mean number of B cells and/or T cells in circulation in other cancer patients. Further provided are methods of predicting the outcome of treating a subject with cancer with the above combination or indicating whether a subject with cancer will benefit from treatment with the above combination. These methods also involve steps (a) and (b). The immune modulating therapy may comprise adoptive T cell therapy, an immune checkpoint blockade inhibitor, or a regulatory T cell (Treg) modulator.
Patent NZ-755149-A (NZ)
Title: Emergency stop apparatus and method for a working machine
Inventor: TAKA MIYAMOTO
IPC: E02F9/16
Filed: 2018-12-28
Abstract: An emergency stop apparatus for a working machine includes a detecting device for detecting an obstacle intruding into a predetermined area around the machine, a power cylinder fixed to a vehicle body of the machine or a member attached to the vehicle body, a coupling member for coupling an output shaft of the power cylinder with a brake pedal, a sensor which detects the position of the shaft and sends a signal back to an electronic control unit. When the obstacle is detected by the detecting device, the electronic control unit actuates the actuator to move the brake pedal in an actuation direction of the service brake to stop the machine. The device keeps people around the machine safe.
Patent NZ-770420-A (NZ)
Title: Method of treatment with histamine-3 receptor inverse agonist
Inventor: NIROGI RAMAKRISHNA
IPC: A61K31/5377
Filed: 2018-08-01
Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson’s disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]- 2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.
Patent NZ-778334-A (NZ)
Title: Audio-based access control
Inventor: MARTENS ROBERT
IPC: G07C9/22
Filed: 2019-12-20
Abstract: A method for authenticating a user based on voice data in an access control system, the method including electrically disconnecting, by an audio detection system of an access control device, a credential reader of the access control device from a controller of the access control device in response to detecting that an input device of the audio detection system has been activated; recording, by the audio detection system, voice data of a user in a vicinity of the access control device in response to electrically disconnecting the credential reader from the controller; authenticating, by the access control system, the user based on the recorded voice data; and performing, by the controller, an access control function in response to authenticating the user based on the recorded voice data.